NYS ADAP Includes New Hep C meds on Formulary
New York State AIDS Drug Assistance Program Adds First HCV Direct-Acting Antiviral (DAA) to its Formulary
Following successful pricing negotiations with Merck, AbbVie and Bristol Myers Squibb by the National ADAP Crisis Task Force, in which New York has a leadership role, the New York State Department of Health, AIDS Drug Assistance Program (ADAP) will be offering access to the following Hepatitis C agents for participants in the state’s AIDS Drug Assistance Program:
- Zepatier (Merck)
- Viekira Pak
- Viekira XR (AbbVie)
- Daklinza (Bristol Myers Squibb)
This formulary addition is effective November 28, 2016.
Last Updated on May 11, 2020 by HepFree NYC
Tags: HepCX News
